Vas Tibor, Kovács Tibor, Késoi István, Sági Balázs, Degrell Péter, Wittmann István, Nagy Judit
Pécsi Tudományegyetem, Klinikai Központ II. Belgyógyászati Klinika és Nefrológiai Centrum Pécs Pacsirta.
Orv Hetil. 2011 Dec 18;152(51):2039-46. doi: 10.1556/OH.2011.29278.
IgA nephropathy is the most common primary glomerulonephritis worldwide. The clinical spectrum covers a wide range of features from minor urinary abnormalities (asymptomatic hematuria and mild proteinuria with normal renal function) to acute and chronic renal insufficiency. Ideally, the goal of treatment would be to correct any defects in IgA1 glycosylation and to modify mesangial deposition or removal of IgA1 deposits. There are only a few randomized controlled trials in IgA nephropathy; for this reason most treatment options are largely based on expert opinion. Authors discuss therapeutic options of different clinical pictures and the optimized renoprotective treatment of all IgA nephropathy patients.
IgA肾病是全球最常见的原发性肾小球肾炎。临床谱涵盖了从轻微尿液异常（无症状血尿和肾功能正常的轻度蛋白尿）到急慢性肾功能不全的广泛特征。理想情况下，治疗目标是纠正IgA1糖基化的任何缺陷，并改变系膜沉积或清除IgA1沉积物。IgA肾病仅有少数随机对照试验；因此，大多数治疗选择很大程度上基于专家意见。作者讨论了不同临床表现的治疗选择以及所有IgA肾病患者的优化肾脏保护治疗。
